Recruiting
Phase 2

DALY II USA/ MB-CART2019.1 for DLBCL

Sponsor:

Miltenyi Biomedicine GmbH

Code:

NCT04792489

Conditions

Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Relapsed Diffuse Large B Cell Lymphoma

High Grade B-cell Lymphoma (HGBCL)

Primary Mediastinal B-cell Lymphoma (PMBCL)

Transformed Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

zamtocabtagene autoleucel (MB-CART2019.1)

Cyclophosphamide

Fludarabine

Bendamustine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information